Side-by-side financials for FATE and GILD. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | FATE | GILD |
|---|---|---|
| Market cap | - | $155.93 B |
| US-listed rank | - | #98 |
| Revenue (latest FY) | $6.65M | $29.44B |
| Net income (latest FY) | -$136.31M | $8.51B |
| Net margin | -2051.1% | 28.9% |
| P/E (trailing FY) | - | 18.3 |
| SEC filings | 827 | 981 |
In their latest fiscal years, FATE THERAPEUTICS INC reported $6.65M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: FATE THERAPEUTICS INC and GILEAD SCIENCES, INC., or browse the full rankings.